{
    "cancer_info": {
        "cancer_name": "Renal Cell Carcinoma (RCC)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Physical Exam",
            "Abdominal/pelvic CT (with/without contrast preferred; renal protocol)",
            "Abdominal/pelvic MRI (if CT contraindicated)",
            "Chest CT (preferred)",
            "Chest X-ray (alternative to CT)",
            "Core needle biopsy",
            "Ureteroscopy",
            "Urine cytology",
            "CBC",
            "Comprehensive metabolic panel (including corrected calcium, creatinine)",
            "LDH",
            "Urinalysis",
            "Genetic testing (for hereditary syndromes)",
            "Bone scan (if elevated ALP or bone pain)",
            "Brain MRI (if neurological symptoms)",
            "Fundoscopy/Ophthalmologic exam",
            "Thyroid Function Tests (TSH)",
            "Blood pressure monitoring",
            "Tumor measurement (RECIST v1.1)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I (T1a)",
            "risk_group": "Localized",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Operable",
                    "plan_name": "Partial nephrectomy",
                    "plan_details": "Surgical removal of tumor with kidney preservation",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Masses ≤3 cm, inoperable",
                    "plan_name": "Ablation",
                    "plan_details": "Cryoablation or radiofrequency ablation",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Alternative"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Masses ≤2 cm/comorbidities",
                    "plan_name": "Active surveillance",
                    "plan_details": "Monitoring without immediate intervention",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Stage I (T1b) and Stage II",
            "risk_group": "Localized",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Partial/Radical nephrectomy",
                    "plan_details": "Surgical resection",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stages II-III",
            "risk_group": "High-risk ccRCC",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Post-nephrectomy",
                    "plan_name": "Pembrolizumab",
                    "plan_details": "Immunotherapy after surgery",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV",
            "risk_group": "ccRCC Favorable (First-line)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "IMDC favorable risk",
                    "plan_name": "Axitinib + Pembrolizumab",
                    "plan_details": "VEGF-TKI + PD-1 inhibitor",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "IMDC favorable risk",
                    "plan_name": "Cabozantinib + Nivolumab",
                    "plan_details": "VEGF/MET inhibitor + PD-1 inhibitor",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV",
            "risk_group": "ccRCC Intermediate/Poor (First-line)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "IMDC intermediate/poor risk",
                    "plan_name": "Ipilimumab + Nivolumab",
                    "plan_details": "CTLA-4 + PD-1 inhibitors",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "IMDC intermediate/poor risk",
                    "plan_name": "Lenvatinib + Pembrolizumab",
                    "plan_details": "VEGF-TKI + PD-1 inhibitor",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV",
            "risk_group": "ccRCC (Subsequent therapy)",
            "treatment_plans": [
                {
                    "treatment_line": "Subsequent treatment",
                    "patient_subgroup": "IO-Naïve",
                    "plan_name": "Cabozantinib",
                    "plan_details": "VEGF/MET inhibitor",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent treatment",
                    "patient_subgroup": "Post-IO",
                    "plan_name": "Belzutifan",
                    "plan_details": "HIF-2α inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV",
            "risk_group": "nccRCC",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All subtypes",
                    "plan_name": "Cabozantinib ± Nivolumab",
                    "plan_details": "VEGF/MET inhibitor ± PD-1 inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Papillary subtype",
                    "plan_name": "Bevacizumab + Erlotinib",
                    "plan_details": "VEGF inhibitor + EGFR-TKI",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Any",
            "risk_group": "VHL-associated RCC",
            "treatment_plans": [
                {
                    "treatment_line": "Systemic therapy",
                    "patient_subgroup": "Tumors requiring intervention",
                    "plan_name": "Belzutifan",
                    "plan_details": "HIF-2α inhibitor (FDA-approved)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Systemic therapy",
                    "patient_subgroup": "Tumors requiring intervention",
                    "plan_name": "Pazopanib",
                    "plan_details": "800 mg orally once daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Any",
            "risk_group": "TSC-associated angiomyolipoma",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Non-surgical candidates",
                    "plan_name": "Everolimus",
                    "plan_details": "mTOR inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "PD-L1 status predicts response to immune checkpoint inhibitors. Sarcomatoid features indicate aggressive disease benefiting from ipilimumab + nivolumab. VHL mutations are targeted by belzutifan (HIF-2α inhibitor). FH mutations (in HLRCC) predict response to erlotinib + bevacizumab. TSC1/2 mutations indicate mTOR pathway activation and response to everolimus. Osteolytic bone lesions require SRE prophylaxis with denosumab or zoledronic acid."
    },
    "guideline_id": "（2025.V3）NCCN临床实践指南：肾癌.txt"
}